The overall goal of this Program is to improve the survival of cancer patients by active specific immunotherapy. To achieve this goal, we will utilize melanoma as a model neoplasm. This renewal application represents a continuation of our previous studies with polyvalent melanoma cell vaccine (PMCV) and investigates the in vivo and in vitro mechanisms of PMCV anticancer activity. The first project is a new project for this renewal which will build on the past successes of this program by utilizing both adoptive and active immunotherapy and targeted vaccine designs to induce antigen specific immune responses. Patients? dendritic cells will be fused with the autologous tumor cells present in the PMCV by electrofusion. Phase I/II clinical trials will be conducted. The second project will continue to utilize already established, as well as developing new, molecular assays using both RNA and DNA markers present in blood and tumors as surrogates to predict disease progression, outcome and treatment efficacy. The third project will complete a randomized Phase III trial in AJCC stage III melanoma to compare PMCV plus BCG compared to BCG alone measuring disease free and overall survival after surgery. This project will also develop an immunological response model for predicting outcomes following vaccine therapy, undertake studies utilizing cytokines to improve vaccine immunotherapy and develop new tumor markers to detect subclinical metastatic disease. All projects rely upon the support of four cores: Administrative and Clinical Support Services, Biostatistics, Serum, Lymphocyte and Tissue Collection, and Molecular Support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012582-33
Application #
6750709
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1977-07-01
Project End
2007-03-31
Budget Start
2004-04-15
Budget End
2005-03-31
Support Year
33
Fiscal Year
2004
Total Cost
$5,176,856
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications